Lyng MB - Search Results

1

Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low density array.

Lyng MB, Laenkholm AV, Pallisgaard N, Vach W, Knoop A, Bak M, Ditzel HJ. Lyng MB, et al. Cell Oncol. 2007;29(5):361-72. doi: 10.1155/2007/860194. Cell Oncol. 2007. PMID: 17726259 Free PMC article.

2

Identification of genes for normalization of real-time RT-PCR data in breast carcinomas.

Lyng MB, Laenkholm AV, Pallisgaard N, Ditzel HJ. Lyng MB, et al. BMC Cancer. 2008 Jan 22;8:20. doi: 10.1186/1471-2407-8-20. BMC Cancer. 2008. PMID: 18211679 Free PMC article.

3

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study.

Lyng MB, Lænkholm AV, Søkilde R, Gravgaard KH, Litman T, Ditzel HJ. Lyng MB, et al. PLoS One. 2012;7(5):e36170. doi: 10.1371/journal.pone.0036170. Epub 2012 May 18. PLoS One. 2012. PMID: 22623953 Free PMC article.

4

Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.

Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ. Kodahl AR, et al. Among authors: lyng mb. Mol Oncol. 2014 Jul;8(5):874-83. doi: 10.1016/j.molonc.2014.03.002. Epub 2014 Mar 16. Mol Oncol. 2014. PMID: 24694649 Free PMC article.

5

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Alves CL, Elias D, Lyng M, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ. Alves CL, et al. Clin Cancer Res. 2016 Nov 15;22(22):5514-5526. doi: 10.1158/1078-0432.CCR-15-1984. Epub 2016 Jun 1. Clin Cancer Res. 2016. PMID: 27252418

6

Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer.

Ditzel HJ, Lyng MB. Ditzel HJ, et al. Among authors: lyng mb. Nat Clin Pract Oncol. 2008 Jul;5(7):376-7. doi: 10.1038/ncponc1139. Epub 2008 May 27. Nat Clin Pract Oncol. 2008. PMID: 18506164 No abstract available.

7

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer.

Gravgaard KH, Lyng MB, Laenkholm AV, Søkilde R, Nielsen BS, Litman T, Ditzel HJ. Gravgaard KH, et al. Among authors: lyng mb. Breast Cancer Res Treat. 2012 Jul;134(1):207-17. doi: 10.1007/s10549-012-1969-9. Breast Cancer Res Treat. 2012. PMID: 22294488

8

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer.

Bjerre C, Knoop A, Bjerre K, Larsen MS, Henriksen KL, Lyng MB, Ditzel HJ, Rasmussen BB, Brünner N, Ejlertsen B, Laenkholm AV. Bjerre C, et al. Among authors: lyng mb. Acta Oncol. 2013 Jan;52(1):82-90. doi: 10.3109/0284186X.2012.734922. Epub 2012 Dec 4. Acta Oncol. 2013. PMID: 23205744

9

Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study.

Lyng MB, Lænkholm AV, Tan Q, Vach W, Gravgaard KH, Knoop A, Ditzel HJ. Lyng MB, et al. PLoS One. 2013;8(1):e54078. doi: 10.1371/journal.pone.0054078. Epub 2013 Jan 16. PLoS One. 2013. PMID: 23342080 Free PMC article.

10

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.

Thomsen KG, Lyng MB, Elias D, Vever H, Knoop AS, Lykkesfeldt AE, Lænkholm AV, Ditzel HJ. Thomsen KG, et al. Among authors: lyng mb. Breast Cancer Res Treat. 2015 Dec;154(3):483-94. doi: 10.1007/s10549-015-3644-4. Epub 2015 Nov 19. Breast Cancer Res Treat. 2015. PMID: 26585578

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters